**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75076

**Manuscript Type:** MINIREVIEWS

**Pancreatic involvement in celiac disease**

Balaban DV *et al*. Pancreas and celiac disease

Daniel Vasile Balaban, Iulia Enache, Marina Ciochina, Alina Popp, Mariana Jinga

**Daniel Vasile Balaban, Iulia Enache, Marina Ciochina, Mariana Jinga,** Department of Internal Medicine and Gastroenterology, Carol Davila University of Medicine and Pharmacy, Bucharest 020021, Romania

**Daniel Vasile Balaban, Iulia Enache, Marina Ciochina, Mariana Jinga,** Dr. Carol Davila Central Military Emergency University Hospital, Bucharest 020021, Romania

**Alina Popp,** Department of Pediatrics, Carol Davila University of Medicine and Pharmacy, Bucharest 020021, Romania

**Alina Popp,** National Institute for Mother and Child Health, Bucharest 020021, Romania

**Author contributions:** Balaban DV proposed the research idea; Balaban DV, Enache I, and Ciochina M performed the literature search and article selection, and drafted the initial version of the manuscript; Popp A and Jinga M critically reviewed the manuscript and supervised the project; All authors contributed to drawing the figures and tables, and have read and approved the final version of the manuscript.

**Corresponding author: Daniel Vasile Balaban, MD, PhD, Senior Lecturer,** Department of Internal Medicine and Gastroenterology, Carol Davila University of Medicine and Pharmacy, 134 Calea Plevnei, Bucharest 020021, Romania. vbalaban@yahoo.com

**Received:** January 15, 2022

**Revised:** April 17, 2022

**Accepted:** May 27, 2022

**Published online:** June 28, 2022

**Abstract**

Celiac disease (CD) is well recognized as a systemic, chronic autoimmune disease mainly characterized by gluten-sensitive enteropathy in genetically predisposed individuals but with various extraintestinal features. One of the affected organs in CD is the pancreas, consisting of both endocrine and exocrine alterations. Over the last decades there has been increasing interest in the pancreatic changes in CD, and this has been reflected by a great number of publications looking at this extraintestinal involvement during the course of CD. While pancreatic endocrine changes in CD, focusing on type 1 diabetes mellitus, are well documented in the literature, the relationship with the exocrine pancreas has been less studied. This review summarizes currently available evidence with regard to pancreatic exocrine alterations in CD, focusing on risk of pancreatitis in CD patients, association with autoimmune pancreatitis, prevalence and outcomes of pancreatic exocrine insufficiency in newly diagnosed and gluten-free diet treated CD patients, and the link with cystic fibrosis. In addition, we discuss mechanisms behind the associated pancreatic exocrine impairment in CD and highlight the recommendations for clinical practice.

**Key Words:** Pancreas; Celiac disease; Autoimmune; Pancreatitis; Cystic fibrosis; Exocrine insufficiency

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Balaban DV, Enache I, Ciochina M, Popp A, Jinga M. Pancreatic involvement in celiac disease. *World J Gastroenterol* 2022; 28(24): 2680-2688

**URL**: https://www.wjgnet.com/1007-9327/full/v28/i24/2680.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v28.i24.2680

**Core Tip:** Celiac disease (CD) is currently regarded as a systemic, chronic, immune-mediated disease triggered by gluten ingestion in genetically susceptible individuals. In the last decade there has been an increasing number of publications on extraintestinal involvement during the course of CD, some of which have assessed the pancreatic changes associated with this disease. This review summarizes currently available data with respect to exocrine pancreatic changes in CD, focusing on practices for clinicians.

**INTRODUCTION**

Celiac disease (CD) is an immune-mediated enteropathy that occurs in genetically predisposed individuals upon ingestion of gluten. Initially considered a small bowel disease, now it is widely recognized as a systemic illness, which accounts for its many protean manifestations. The systemic character along with its various clinical presentations make CD a sometimes difficult to recognize clinical chameleon. The wide spectrum of presenting features, sometimes subclinical, hinders case-finding strategies and delays diagnosis, as CD is often not considered among the differential diagnoses[1,2]. Moreover, there is also the further drawback of poor awareness among different medical specialties[3].

Among the extraintestinal features of CD[4–6], pancreatic involvement has rarely been reported compared to other organ-specific manifestations such as cutaneous, hematologic, liver-related, rheumatologic, cardiovascular, or neurological impairments[7–13]. Moreover, while some of these systemic features have been incorporated into case-finding and screening strategies such as anemia, osteoporosis or chronic liver disease[14], pancreatic-associated involvement in CD is scarcely reported in currently available guidelines[15–17]. The association between the pancreas and CD covered in guidelines is limited to the need to consider pancreatic exocrine insufficiency (PEI) as an alternative diagnosis in non-responsive CD and the fact that upper gastrointestinal surgery including pancreas-related indications may unmask subclinical CD[15,16]. This has also been highlighted by previous reports on the impact of CD on exocrine and endocrine pancreas, which also set the need for further research focused on this association[18]. Contrasting the well-documented pancreatic endocrine changes in CD, referring to type 1 diabetes mellitus in particular, the relationship with the exocrine pancreas has been less covered in the literature.

On the other hand, the wide spectrum of pancreatic diseases does not include CD as a risk factor or associated condition, except counting CD as a potential cause of PEI[19]. Pancreatic involvement can occur in patients with CD, either caused by the small-bowel disease or co-existing with it. The main mechanisms for this association are believed to be the impaired cholecystokinin (CCK) and secretin release, but also the chronic duodenal inflammation that can lead to secondary modifications of papillary mucosal area[20].

Our aim was to summarize currently available evidence with regard to exocrine pancreatic involvement in CD, looking at CD as a risk factor or associated condition with pathologies of the exocrine pancreas, and testing indications regarding the bidirectional association of the two diseases.

**Search strategy**

For this purpose, we searched PubMed in January 2022 for all publications on the association between pancreas and CD, using the medical subject headings (MeSH) terms–“pancreas” (ID: D010179) and “celiac disease” (ID: D002446), with the following search syntax (("pancreas" [Mesh]) OR (pancreas [Title/Abstract])) AND (("celiac disease" [Mesh]) OR (celiac disease [Title/Abstract])). We performed additional searches with pancreas-related terms, “Pancreas, exocrine” (ID: D046790), “pancreatitis” (ID: D010195), “pancreatitis, chronic” (ID: D050500), “autoimmune pancreatitis” (ID: D000081012) and “celiac disease” (ID: D002446). The extended search yielded a total of 889 results, of which 145 were duplicates. Search results were imported into Reference Citation Analysis (Baishideng Publishing Group, Inc.), which was used for article processing and selection. We filtered the search for reviews, editorials, comments and opinion articles (*n* = 140). We excluded papers referring to the association of CD with diabetes or alterations of the endocrine pancreas (*n* = 66). The remaining titles and consecutive abstracts were screened for pertinence to the topic. We selected relevant articles on exocrine pancreatic involvement in CD for full-text analysis and summarized findings according to significant associations. References and citing articles of selected papers were also analyzed for potentially relevant articles that might have been missed in the initial search. The process of article selection is detailed in Figure 1.

**CD and risk of pancreatitis**

CD patients are at risk both for acute pancreatitis (AP) and chronic pancreatitis (CP)[21–23]. While some have described worse outcomes and increased medical burden among CD individuals[21], others have found lower morbidity and mortality among this patient group[24] (Table 1).

Several pathogenic mechanisms have been theorized to account for the elevated pancreatitis risk in CD–malnutrition, papillary stenosis, and immune phenomena[25] (Figure 2). Severe malnutrition affects pancreatic secretion and can cause pancreatic atrophy[26]. Also, chronic inflammation of the duodenal mucosa in CD patients can also involve the papillary area and lead to papillary stenosis and consequent pancreatic disease[20]. Finally, autoimmune pancreatitis (AIP) or other autoimmune phenomena such as islet-specific autoantibodies in CD-associated type 1 diabetes mellitus can contribute to the link between pancreatitis and CD[27,28].

With regard to CP, results are also discordant using similar diagnostic criteria; while some authors have reported CP features to be common in CD patients undergoing endoscopic ultrasound (EUS) assessment[29], others did not reveal significant structural alterations in the pancreatic parenchyma of CD individuals[30]. In their study using EUS criteria and elastography, Rana *et al*[30] concluded that PEI is functional and reversible after gluten-free diet (GFD). Supporting this finding, the pathognomonic pancreatic calcifications have been rarely reported in CD[31–35]. However, a biopsy-based study published as abstract has shown CD prevalence as high as 7.4% in established CP, recommending screening in this group[36].

Concerning CD screening in pancreatic diseases, there have been reports of asymptomatic hyperenzymemia, macrolipasemia, or macroamylasemia[37-42] in CD patients, but prevalence studies are missing. According to these reports, decrease or even resolution of macroamylasemia/macrolipasemia or elevated pancreatic enzyme levels can be seen on GFD. Of note, the occurrence of hyperenzymemia in CD can be a confounder for the reported elevated risk of AP associated with CD, by overdiagnosing AP in this scenario.

On the other hand, idiopathic recurrent pancreatitis and sphincter of Oddi dysfunction might be considered a testing indication for CD, given the mechanism of chronic papillitis[20,43]. Non-response to treatment in CP might warrant testing for CD, as suggested in some case reports[31].

**Exocrine pancreatic insufficiency and CD**

CD is a well-recognized less common etiology of PEI[19,44,45]. This is well reported in currently available guidelines[46]. EPI has been reported with variable frequency in CD patients, depending on the test used to diagnose it. Early studies were based on direct pancreatic function testing (pancreatic enzyme or bicarbonate secretions measurements) and found that PEI is common in classical CD, but non-severe[47]. Fecal elastase (FE) is recommended for detecting PEI in newly diagnosed CD[48]. Impairment of pancreatic exocrine function can be seen both in newly diagnosed CD, in up to 80% of cases[19], and in treated CD, where it should be considered a cause of treatment failure in patients unresponsive to GFD[49,50]. In this latter group comprising GFD-treated CD patients with continuing diarrhea, EPI has been reported in 12%-18% of cases[51,52]. While CD patients improve with pancreatic enzyme replacement therapy (PERT), probably paralleling the restoring of mucosal architecture on GFD, some authors have reported that PERT could be discontinued in some patients who experience improvement in symptoms[53]. However, in CD patients with PEI, who report good adherence to GFD but experience continued malabsorption with adequate dosing PERT, additional pathogenic mechanisms such as enteric infections (*e.g.*, *Giardia*), small intestinal bacterial overgrowth, or complications such as refractory CD and enteropathy associated T-cell lymphoma should be sought[54]. Moreover, gastroparesis in the setting of type 1 diabetes mellitus associated with CD could contribute to incomplete response to PERT. PEI should be readily recognized in slowly recovering children with CD on GFD, as it might accelerate weight increase with adequate enzyme supplementation[55].

Correlation of certain genetic polymorphisms with PEI has also been studied, but without conclusive associations in a small cohort of CD patients[56].

A concern with using FE is represented by the lower diagnostic accuracy compared to direct pancreatic function testing, variability among different tests and analytical processing of samples, taking into account the potential dilution due to diarrhea[57–59].

Despite the increased risk of pancreatitis in CD discussed above, changes in pancreatic enzyme secretion in these patients seen to be mainly functional, as reported by Rana *et al*[30], who found no correlation with structural parenchymal alterations, assessed by EUS. Another study, based on magnetic resonance imaging assessment, did not reveal morphological changes in CD patients with PEI[60]. This impaired function of the exocrine pancreas is also supported by the inverse correlation between mucosal damage and pancreatic enzyme levels, with reversal of PEI on GFD[19,61]. However, protein malnutrition, also present in CD patients, has been shown to be associated with acinar cell atrophy and fibrosis[18].

The main mechanism of PEI in CD patients is disruption of mucosal release of enteric hormones, mainly CCK and secretin, which represent a potent stimulus for pancreatic function. While exocrine pancreatic function is intrinsically normal, impaired CCK and secretin release from the atrophic mucosa leads to decreased secretion of enzymes into the duodenal lumen. The functional PEI that occurs in CD is reversible upon exogenous administration of CCK-pancreozymin[62]. Others have suggested that PEI can develop independent of this reduced entero-hormone release[63]. Another theorized mechanism is deficiency of amino acids, which leads to reduced protein synthesis for pancreatic enzymes. This mechanism is also backed up by the fact that correction of deficiencies alleviates PEI in CD patients[64]. Another hypothesis, but probably of less significance, is that of structural changes in the pancreatic parenchyma (acinar atrophy, fibrosis) seen in advanced malnutrition[65]. Mechanisms behind EPI in CD are summarized in Table 2[18,47,50,66].

**Cystic fibrosis and CD**

Another underrecognized, pancreas-related association for CD is cystic fibrosis (CF), an autosomal recessive disease characterized by mutations in the CF transmembrane conductance regulator gene, which encodes a chloride and bicarbonate channel expressed in epithelial cells in multiple organs[67]. While the pancreatic dysfunction in CF is well known, altered immune regulation has been described in these patients, which predisposes them to developing autoimmune phenomena. The systematic review and meta-analysis by Imrei *et al*[68] showed pooled prevalence of 1.8%-2.3% of biopsy-proven CD among CF patients, which is more than twice that of the general population[69]. Based on this observation, the authors recommend routine screening for CD in CF patients. This recommendation is supported by another group[70], who suggested performing CD screening in CF with persistent gastrointestinal symptoms or malabsorption (including improper weight and/or height gain in pediatric patients), despite adequate enzyme replacement therapy.

**AIP and CD**

AIP is a chronic fibroinflammatory disease of the pancreas, with a relapsing steroid-responsive pattern. Given the common immune dysregulation background of both AIP and CD, researchers have looked whether there is an association of the two. While some isolated reports have shown a potential link between AIP and CD[71,72], a study looking at CD frequency in a cohort of AIP patients did not show an increased CD prevalence among this group (1.4%) and concluded that serologic screening for CD is not supported[73]. However, a murine model of AIP has provided insight that gliadin sensitization and challenge can induce pancreatitis and extrapancreatic inflammation in HLA-DQ8 transgenic mice[74]. On the other hand, immunoglobulin G4-positive cells, which have been searched for in duodenal/ampullary biopsies as an alternative to pancreatic biopsy for diagnosing AIP, have also been reported in 7 of 18 CD patients in the study by Cebe *et al*[75]. Given the scarce data on AIP and CD, further research is warranted to conclude if there is a link between the two beyond the plausible biologic mechanism. A recognized association is that of type 2 AIP and ulcerative colitis, and considering the also established connection between CD and inflammatory bowel diseases[76], linking the three diseases might provide some insight on the relationship between AIP and CD.

**CONCLUSION**

Pancreatic involvement, both endocrine and exocrine, is frequent in CD and should be searched for in the appropriate clinical setting. Conversely, certain pancreatic-related diseases should prompt looking for CD–CF with ongoing digestive symptoms, non-responsive CP, idiopathic recurrent pancreatitis. Concomitant pancreatic disease in a CD patient may contribute to aggravated malnutrition and should be readily recognized in order to improve nutritional status and prognosis. Also, there is increasing data that impaired pancreatic function in CD can improve on a GFD.

**REFERENCES**

1 **Makharia GK**, Singh P, Catassi C, Sanders DS, Leffler D, Ali RAR, Bai JC. The global burden of coeliac disease: opportunities and challenges. *Nat Rev Gastroenterol Hepatol* 2022 [PMID: 34980921 DOI: 10.1038/s41575-021-00552-z]

2 **Pinto-Sanchez MI**, Silvester JA, Lebwohl B, Leffler DA, Anderson RP, Therrien A, Kelly CP, Verdu EF. Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 875-884 [PMID: 34526700 DOI: 10.1038/s41575-021-00511-8]

3 **Jinga M**, Popp A, Balaban DV, Dima A, Jurcut C. Physicians' attitude and perception regarding celiac disease: A questionnaire-based study. *Turk J Gastroenterol* 2018; **29**: 419-426 [PMID: 30249556 DOI: 10.5152/tjg.2018.17236]

4 **Therrien A**, Kelly CP, Silvester JA. Celiac Disease: Extraintestinal Manifestations and Associated Conditions. *J Clin Gastroenterol* 2020; **54**: 8-21 [PMID: 31513026 DOI: 10.1097/MCG.0000000000001267]

5 **Leffler DA**, Green PH, Fasano A. Extraintestinal manifestations of coeliac disease. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 561-571 [PMID: 26260366 DOI: 10.1038/nrgastro.2015.131]

6 **Durazzo M**, Ferro A, Brascugli I, Mattivi S, Fagoonee S, Pellicano R. Extra-Intestinal Manifestations of Celiac Disease: What Should We Know in 2022? *J Clin Med* 2022; **11** [PMID: 35011999 DOI: 10.3390/jcm11010258]

7 **Balaban DV**, Mihai A, Dima A, Popp A, Jinga M, Jurcut C. Celiac disease and Sjögren's syndrome: A case report and review of literature. *World J Clin Cases* 2020; **8**: 4151-4161 [PMID: 33024773 DOI: 10.12998/wjcc.v8.i18.4151]

8 **Dima A**, Jurcut C, Jinga M. Rheumatologic manifestations in celiac disease: what should we remember? *Rom J Intern Med* 2019; **57**: 3-5 [PMID: 30375355 DOI: 10.2478/rjim-2018-0024]

9 **Ciaccio EJ**, Lewis SK, Biviano AB, Iyer V, Garan H, Green PH. Cardiovascular involvement in celiac disease. *World J Cardiol* 2017; **9**: 652-666 [PMID: 28932354 DOI: 10.4330/wjc.v9.i8.652]

10 **Haggård L**, Glimberg I, Lebwohl B, Sharma R, Verna EC, Green PHR, Ludvigsson JF. High prevalence of celiac disease in autoimmune hepatitis: Systematic review and meta-analysis. *Liver Int* 2021; **41**: 2693-2702 [PMID: 34219350 DOI: 10.1111/liv.15000]

11 **Mearns ES**, Taylor A, Thomas Craig KJ, Puglielli S, Leffler DA, Sanders DS, Lebwohl B, Hadjivassiliou M. Neurological Manifestations of Neuropathy and Ataxia in Celiac Disease: A Systematic Review. *Nutrients* 2019; **11** [PMID: 30759885 DOI: 10.3390/nu11020380]

12 **Rodrigo L**, Beteta-Gorriti V, Alvarez N, Gómez de Castro C, de Dios A, Palacios L, Santos-Juanes J. Cutaneous and Mucosal Manifestations Associated with Celiac Disease. *Nutrients* 2018; **10** [PMID: 29933630 DOI: 10.3390/nu10070800]

13 **Laurikka P**, Nurminen S, Kivelä L, Kurppa K. Extraintestinal Manifestations of Celiac Disease: Early Detection for Better Long-Term Outcomes. *Nutrients* 2018; **10** [PMID: 30081502 DOI: 10.3390/nu10081015]

14 **Elwenspoek MMC**, Jackson J, O'Donnell R, Sinobas A, Dawson S, Everitt H, Gillett P, Hay AD, Lane DL, Mallett S, Robins G, Watson JC, Jones HE, Whiting P. The accuracy of diagnostic indicators for coeliac disease: A systematic review and meta-analysis. *PLoS One* 2021; **16**: e0258501 [PMID: 34695139 DOI: 10.1371/journal.pone.0258501]

15 **Al-Toma A**, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol J* 2019; **7**: 583-613 [PMID: 31210940 DOI: 10.1177/2050640619844125]

16 **Rubio-Tapia A**, Hill ID, Kelly CP, Calderwood AH, Murray JA; American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol* 2013; **108**: 656-76; quiz 677 [PMID: 23609613 DOI: 10.1038/ajg.2013.79]

17 **Ludvigsson JF**, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, Green PH, Hadjivassiliou M, Holdoway A, van Heel DA, Kaukinen K, Leffler DA, Leonard JN, Lundin KE, McGough N, Davidson M, Murray JA, Swift GL, Walker MM, Zingone F, Sanders DS; BSG Coeliac Disease Guidelines Development Group; British Society of Gastroenterology. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. *Gut* 2014; **63**: 1210-1228 [PMID: 24917550 DOI: 10.1136/gutjnl-2013-306578]

18 **Freeman HJ**. Pancreatic endocrine and exocrine changes in celiac disease. *World J Gastroenterol* 2007; **13**: 6344-6346 [PMID: 18081222 DOI: 10.3748/wjg.v13.i47.6344]

19 **Singh VK**, Haupt ME, Geller DE, Hall JA, Quintana Diez PM. Less common etiologies of exocrine pancreatic insufficiency. *World J Gastroenterol* 2017; **23**: 7059-7076 [PMID: 29093615 DOI: 10.3748/wjg.v23.i39.7059]

20 **Patel RS**, Johlin FC Jr, Murray JA. Celiac disease and recurrent pancreatitis. *Gastrointest Endosc* 1999; **50**: 823-827 [PMID: 10570344 DOI: 10.1016/s0016-5107(99)70166-5]

21 **Alkhayyat M**, Saleh MA, Abureesh M, Khoudari G, Qapaja T, Mansoor E, Simons-Linares CR, Vargo J, Stevens T, Rubio-Tapia A, Chahal P. The Risk of Acute and Chronic Pancreatitis in Celiac Disease. *Dig Dis Sci* 2021; **66**: 2691-2699 [PMID: 32809104 DOI: 10.1007/s10620-020-06546-2]

22 **Sadr-Azodi O**, Sanders DS, Murray JA, Ludvigsson JF. Patients with celiac disease have an increased risk for pancreatitis. *Clin Gastroenterol Hepatol* 2012; **10**: 1136-1142.e3 [PMID: 22801059 DOI: 10.1016/j.cgh.2012.06.023]

23 **Ludvigsson JF**, Montgomery SM, Ekbom A. Risk of pancreatitis in 14,000 individuals with celiac disease. *Clin Gastroenterol Hepatol* 2007; **5**: 1347-1353 [PMID: 17702659 DOI: 10.1016/j.cgh.2007.06.002]

24 **Osagiede O**, Lukens FJ, Wijarnpreecha K, Corral JE, Raimondo M, Kröner PT. Acute Pancreatitis in Celiac Disease: Has the Inpatient Prevalence Changed and Is It Associated With Worse Outcomes? *Pancreas* 2020; **49**: 1202-1206 [PMID: 32898005 DOI: 10.1097/MPA.0000000000001657]

25 **Basha J**, Appasani S, Vaiphei K, Singh K, Kochhar R. Celiac disease presenting as recurrent pancreatitis and pseudocyst. *JOP* 2012; **13**: 533-535 [PMID: 22964961 DOI: 10.6092/1590-8577/1091]

26 **Brooks SE**, Golden MH. The exocrine pancreas in kwashiorkor and marasmus. Light and electron microscopy. *West Indian Med J* 1992; **41**: 56-60 [PMID: 1523833]

27 **Leeds JS**, Sanders DS. Risk of pancreatitis in patients with celiac disease: is autoimmune pancreatitis a biologically plausible mechanism? *Clin Gastroenterol Hepatol* 2008; **6**: 951; author reply 951 [PMID: 18674737 DOI: 10.1016/j.cgh.2007.12.025]

28 **Sasamori H**, Fukui T, Hayashi T, Yamamoto T, Ohara M, Yamamoto S, Kobayashi T, Hirano T. Analysis of pancreatic volume in acute-onset, slowly-progressive and fulminant type 1 diabetes in a Japanese population. *J Diabetes Investig* 2018; **9**: 1091-1099 [PMID: 29427469 DOI: 10.1111/jdi.12816]

29 **Kumar S**, Gress F, Green PH, Lebwohl B. Chronic Pancreatitis is a Common Finding in Celiac Patients Who Undergo Endoscopic Ultrasound. *J Clin Gastroenterol* 2019; **53**: e128-e129 [PMID: 27749638 DOI: 10.1097/MCG.0000000000000726]

30 **Rana SS**, Dambalkar A, Chhabra P, Sharma R, Nada R, Sharma V, Rana S, Bhasin DK. Is pancreatic exocrine insufficiency in celiac disease related to structural alterations in pancreatic parenchyma? *Ann Gastroenterol* 2016; **29**: 363-366 [PMID: 27366039 DOI: 10.20524/aog.2016.0042]

31 **Rana SS**, Bhasin DK, Sinha SK, Singh K. Coexistence of chronic calcific pancreatitis and celiac disease. *Indian J Gastroenterol* 2007; **26**: 150; author reply 150 [PMID: 17704598]

32 **Pitchumoni CS**, Thomas E, Balthazar E, Sherling B. Chronic calcific pancreatitis in association with celiac disease. *Am J Gastroenterol* 1977; **68**: 358-361 [PMID: 605891]

33 **FITZGERALD O**, FITZGERALD P, FENNELLY J, MCMULLIN JP, BOLAND SJ. A CLINICAL STUDY OF CHRONIC PANCREATITIS. *Gut* 1963; **4**: 193-216 [PMID: 14058261 DOI: 10.1136/gut.4.3.193]

34 **Nanda R**, Anand BS. Celiac disease and tropical calcific pancreatitis. *Am J Gastroenterol* 1993; **88**: 1790-1792 [PMID: 8213729]

35 **Arya S**, Rana SS, Sinha SK, Nagi B, Bhasin DK. Celiac disease and chronic calcific pancreatitis with pancreas divisum. *Gastrointest Endosc* 2006; **63**: 1080-1081 [PMID: 16733138 DOI: 10.1016/j.gie.2006.01.001]

36 **Nett A,** Wamsterker E, DiMagno M. Should Patients With Established Chronic Pancreatitis Undergo Testing for Celiac Disease? Abstracts of Papers Submitted to the 47th Meeting of the American Pancreatic Association, October 26–29, 2016, Boston, Massachusetts. Pancreas 2016: 1494–551

37 **Rabsztyn A**, Green PH, Berti I, Fasano A, Perman JA, Horvath K. Macroamylasemia in patients with celiac disease. *Am J Gastroenterol* 2001; **96**: 1096-1100 [PMID: 11316153 DOI: 10.1111/j.1572-0241.2001.03746.x]

38 **Bonetti G**, Serricchio G, Giudici A, Bettonagli M, Vadacca GB, Bruno R, Coslovich E, Moratti R. Hyperamylasemia due to macroamylasemia in adult gluten enteropathy. *Scand J Clin Lab Invest* 1997; **57**: 271-273 [PMID: 9238763 DOI: 10.3109/00365519709060036]

39 **Bermejo JF**, Carbone J, Rodriguez JJ, Macias R, Rodriguez M, Gil J, Marin MA, Torres F, Fernandez-Cruz E. Macroamylasaemia, IgA hypergammaglobulinaemia and autoimmunity in a patient with Down syndrome and coeliac disease. *Scand J Gastroenterol* 2003; **38**: 445-447 [PMID: 12739720 DOI: 10.1080/00365520310000933]

40 **Barera G**, Bazzigaluppi E, Viscardi M, Renzetti F, Bianchi C, Chiumello G, Bosi E. Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. *Pediatrics* 2001; **107**: E93 [PMID: 11389291 DOI: 10.1542/peds.107.6.e93]

41 **La Villa G**, Pantaleo P, Tarquini R, Cirami L, Perfetto F, Mancuso F, Laffi G. Multiple immune disorders in unrecognized celiac disease: a case report. *World J Gastroenterol* 2003; **9**: 1377-1380 [PMID: 12800261 DOI: 10.3748/wjg.v9.i6.1377]

42 **Liu Z**, Wang J, Qian J, Tang F. Hyperamylasemia, reactive plasmacytosis, and immune abnormalities in a patient with celiac disease. *Dig Dis Sci* 2007; **52**: 1444-1447 [PMID: 17443408 DOI: 10.1007/s10620-006-9268-0]

43 **Rodrigo L**, Alvarez N, Riestra S, de Francisco R, González Bernardo O, García Isidro L, López Vázquez A, López Larrea C. [Relapsing acute pancreatitis associated with gluten enteropathy. Clinical, laboratory, and evolutive characteristics in thirty-four patients]. *Rev Esp Enferm Dig* 2008; **100**: 746-751 [PMID: 19222332 DOI: 10.4321/s1130-01082008001200002]

44 **Kunovský L**, Dítě P, Jabandžiev P, Eid M, Poredská K, Vaculová J, Sochorová D, Janeček P, Tesaříková P, Blaho M, Trna J, Hlavsa J, Kala Z. Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis. *J Clin Med* 2021; **10** [PMID: 34945075 DOI: 10.3390/jcm10245779]

45 **Leeds JS**, Hopper AD, Hurlstone DP, Edwards SJ, McAlindon ME, Lobo AJ, Donnelly MT, Morley S, Sanders DS. Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? *Aliment Pharmacol Ther* 2007; **25**: 265-271 [PMID: 17269988 DOI: 10.1111/j.1365-2036.2006.03206.x]

46 **Gheorghe C**, Seicean A, Saftoiu A, Tantau M, Dumitru E, Jinga M, Negreanu L, Mateescu B, Gheorghe L, Ciocirlan M, Cijevschi C, Constantinescu G, Dima S, Diculescu M; Romanian Association for Pancreatic Pathology. Romanian guidelines on the diagnosis and treatment of exocrine pancreatic insufficiency. *J Gastrointestin Liver Dis* 2015; **24**: 117-123 [PMID: 25822444 DOI: 10.15403/jgld.2014.1121.app]

47 **DiMagno M**. Exocrine Pancreatic Insufficiency and Pancreatitis Associated with Celiac Disease [Internet]. [cited 10 January 2022]. Available from: https://pancreapedia.org/sites/default/files/Exocrine-Pancreatic-Insufficiency-Pancreatitis-Celiac-Disease\_0.pdf

48 **Pezzilli R**. Exocrine pancreas involvement in celiac disease: a review. *Recent Pat Inflamm Allergy Drug Discov* 2014; **8**: 167-172 [PMID: 25417707 DOI: 10.2174/1872213x08666141122210738]

49 **Weizman Z**, Hamilton JR, Kopelman HR, Cleghorn G, Durie PR. Treatment failure in celiac disease due to coexistent exocrine pancreatic insufficiency. *Pediatrics* 1987; **80**: 924-926 [PMID: 3684405]

50 **Regan PT**, DiMagno EP. Exocrine pancreatic insufficiency in celiac sprue: a cause of treatment failure. *Gastroenterology* 1980; **78**: 484-487 [PMID: 7351287]

51 **Fine KD**, Meyer RL, Lee EL. The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. *Gastroenterology* 1997; **112**: 1830-1838 [PMID: 9178673 DOI: 10.1053/gast.1997.v112.pm9178673]

52 **Abdulkarim AS**, Burgart LJ, See J, Murray JA. Etiology of nonresponsive celiac disease: results of a systematic approach. *Am J Gastroenterol* 2002; **97**: 2016-2021 [PMID: 12190170 DOI: 10.1111/j.1572-0241.2002.05917.x]

53 **Evans KE**, Leeds JS, Morley S, Sanders DS. Pancreatic insufficiency in adult celiac disease: do patients require long-term enzyme supplementation? *Dig Dis Sci* 2010; **55**: 2999-3004 [PMID: 20458623 DOI: 10.1007/s10620-010-1261-y]

54 **Struyvenberg MR**, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency - Breaking the myths. *BMC Med* 2017; **15**: 29 [PMID: 28183317 DOI: 10.1186/s12916-017-0783-y]

55 **Carroccio A**, Iacono G, Lerro P, Cavataio F, Malorgio E, Soresi M, Baldassarre M, Notarbartolo A, Ansaldi N, Montalto G. Role of pancreatic impairment in growth recovery during gluten-free diet in childhood celiac disease. *Gastroenterology* 1997; **112**: 1839-1844 [PMID: 9178674 DOI: 10.1053/gast.1997.v112.pm9178674]

56 **Licul V**, Cizmarević NS, Ristić S, Mikolasević I, Mijandrusić BS. CTLA-4 +49 and TNF-alpha-308 gene polymorphisms in celiac patients with exocrine pancreatic insufficiency. *Coll Antropol* 2013; **37**: 1191-1194 [PMID: 24611333]

57 **Brydon WG**, Kingstone K, Ghosh S. Limitations of faecal elastase-1 and chymotrypsin as tests of exocrine pancreatic disease in adults. *Ann Clin Biochem* 2004; **41**: 78-81 [PMID: 14713391 DOI: 10.1258/000456304322664753]

58 **Kampanis P**, Ford L, Berg J. Development and validation of an improved test for the measurement of human faecal elastase-1. *Ann Clin Biochem* 2009; **46**: 33-37 [PMID: 19008259 DOI: 10.1258/acb.2008.008123]

59 **Vanga RR**, Tansel A, Sidiq S, El-Serag HB, Othman MO. Diagnostic Performance of Measurement of Fecal Elastase-1 in Detection of Exocrine Pancreatic Insufficiency: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2018; **16**: 1220-1228.e4 [PMID: 29374614 DOI: 10.1016/j.cgh.2018.01.027]

60 **Vujasinovic M**, Tepes B, Volfand J, Rudolf S. Exocrine pancreatic insufficiency, MRI of the pancreas and serum nutritional markers in patients with coeliac disease. *Postgrad Med J* 2015; **91**: 497-500 [PMID: 26253920 DOI: 10.1136/postgradmedj-2015-133262]

61 **Nousia-Arvanitakis S**, Karagiozoglou-Lamboudes T, Aggouridaki C, Malaka-Lambrellis E, Galli-Tsinopoulou A, Xefteri M. Influence of jejunal morphology changes on exocrine pancreatic function in celiac disease. *J Pediatr Gastroenterol Nutr* 1999; **29**: 81-85 [PMID: 10400109 DOI: 10.1097/00005176-199907000-00019]

62 **DiMagno EP**, Go WL, Summerskill WH. Impaired cholecystokinin-pancreozymin secretion, intraluminal dilution, and maldigestion of fat in sprue. *Gastroenterology* 1972; **63**: 25-32 [PMID: 5055745]

63 **Carroccio A**, Iacono G, Montalto G, Cavataio F, Di Marco C, Balsamo V, Notarbartolo A. Exocrine pancreatic function in children with coeliac disease before and after a gluten free diet. *Gut* 1991; **32**: 796-799 [PMID: 1855688 DOI: 10.1136/gut.32.7.796]

64 **Tandon BN**, Banks PA, George PK, Sama SK, Ramachandran K, Gandhi PC. Recovery of exocrine pancreatic function in adult protein-calorie malnutrition. *Gastroenterology* 1970; **58**: 358-362 [PMID: 5437989]

65 **Tandon BN**, George PK, Sama SK, Ramachandran K, Gandhi PC. Exocrine pancreatic function in protein--calorie malnutrition disease of adults. *Am J Clin Nutr* 1969; **22**: 1476-1482 [PMID: 5350763 DOI: 10.1093/ajcn/22.11.1476]

66 **Buchan AM**, Grant S, Brown JC, Freeman HJ. A quantitative study of enteric endocrine cells in celiac sprue. *J Pediatr Gastroenterol Nutr* 1984; **3**: 665-671 [PMID: 6150077 DOI: 10.1097/00005176-198411000-00004]

67 **Shteinberg M**, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. *Lancet* 2021; **397**: 2195-2211 [PMID: 34090606 DOI: 10.1016/S0140-6736(20)32542-3]

68 **Imrei M**, Németh D, Szakács Z, Hegyi P, Kiss S, Alizadeh H, Dembrovszky F, Pázmány P, Bajor J, Párniczky A. Increased Prevalence of Celiac Disease in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis. *J Pers Med* 2021; **11** [PMID: 34575636 DOI: 10.3390/jpm11090859]

69 **Singh P**, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, Makharia GK. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2018; **16**: 823-836.e2 [PMID: 29551598 DOI: 10.1016/j.cgh.2017.06.037]

70 **Emiralioglu N**, Ademhan Tural D, Hizarcioglu Gulsen H, Ergen YM, Ozsezen B, Sunman B, Saltık Temizel İ, Yalcin E, Dogru D, Ozcelik U, Kiper N. Does cystic fibrosis make susceptible to celiac disease? *Eur J Pediatr* 2021; **180**: 2807-2813 [PMID: 33765186 DOI: 10.1007/s00431-021-04011-4]

71 **Patel BJ**, Cantor M, Retrosi G, Gheorghe R, Wrogemann J, Mujawar Q. Autoimmune Pancreatitis Masquerading as Celiac Disease. *Pancreas* 2019; **48**: e53-e54 [PMID: 31206470 DOI: 10.1097/MPA.0000000000001326]

72 **Masoodi I**, Wani H, Alsayari K, Sulaiman T, Hassan NS, Nazmi Alqutub A, Al Omair A, H Al-Lehibi A. Celiac disease and autoimmune pancreatitis: an uncommon association. A case report. *Eur J Gastroenterol Hepatol* 2011; **23**: 1270-1272 [PMID: 21946127 DOI: 10.1097/MEG.0b013e32834c7bad]

73 **De Marchi G**, Zanoni G, Conti Bellocchi MC, Betti E, Brentegani M, Capelli P, Zuliani V, Frulloni L, Klersy C, Ciccocioppo R. There Is No Association between Coeliac Disease and Autoimmune Pancreatitis. *Nutrients* 2018; **10** [PMID: 30149525 DOI: 10.3390/nu10091157]

74 **Moon SH**, Kim J, Kim MY, Park do H, Song TJ, Kim SA, Lee SS, Seo DW, Lee SK, Kim MH. Sensitization to and Challenge with Gliadin Induce Pancreatitis and Extrapancreatic Inflammation in HLA-DQ8 Mice: An Animal Model of Type 1 Autoimmune Pancreatitis. *Gut Liver* 2016; **10**: 842-850 [PMID: 27114422 DOI: 10.5009/gnl15484]

75 **Cebe KM**, Swanson PE, Upton MP, Westerhoff M. Increased IgG4+ cells in duodenal biopsies are not specific for autoimmune pancreatitis. *Am J Clin Pathol* 2013; **139**: 323-329 [PMID: 23429368 DOI: 10.1309/AJCPT00NHQHXAHDS]

76 **Pinto-Sanchez MI**, Seiler CL, Santesso N, Alaedini A, Semrad C, Lee AR, Bercik P, Lebwohl B, Leffler DA, Kelly CP, Moayyedi P, Green PH, Verdu EF. Association Between Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-Analysis. *Gastroenterology* 2020; **159**: 884-903.e31 [PMID: 32416141 DOI: 10.1053/j.gastro.2020.05.016]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** European Society for Gastrointestinal Endoscopy, No. 45910264; Association for Pancreatic Pathology Romania; European Society for the Study of Coeliac Disease (ESsCD); Romanian Society of Gastroenterology and Hepatology; Romanian Society of Digestive Endoscopy; European Pancreatic Club; World Endoscopy Organization

**Peer-review started:** January 15, 2022

**First decision:** April 12, 2022

**Article in press:** May 27, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Romania

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Ashkar M, United States; Ghazanfar A, United Kingdom; Lee Y, South Korea **A-Editor:** Yao (Online Science Editor) QG, China **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Fan JR

**Figure Legends**

****

**Figure 1 Flow diagram of the article selection process.**

****

**Figure 2 Mechanism behind the increased pancreatitis risk in celiac disease patients.**

**Table 1 Summary of studies looking at acute pancreatitis and chronic pancreatitis prevalence among individuals with celiac disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ref. | CD, *n* | Pancreatitis prevalence | OR of AP | Outcome |
| Alkhayyat *et al*[21], 2021 | 133400 | AP 1.06%; CP 0.52% | OR for AP = 2.66; OR for CP = 2.18 | Worse outcomes compared to non-CD |
| Osagiede *et al*[24], 2020 | 337201 | AP 2.2% | OR = 1.92 | Lower morbidity and mortality, attributed to less severe forms of AP or lower baseline comorbidities |
| Sadr-Azodi *et al*[22], 2012 | 28908 | Pancreatitis 1.4% | HR for gallstone-related AP = 1.59; HR for non-gallstone-related AP = 1.86; HR for CP = 3.33 | Increased risk of severe AP (gallstone-related: HR = 3.18; non-gallstone related: HR = 2.00) |
| Ludvigsson *et al*[23], 2007 | 14239 | Pancreatitis any type 0.66% | HR for pancreatitis of any type = 3.3; HR for CP = 19.8 | Patient population was represented by hospital inpatients, leaving out those managed as outpatients |

AP: Acute pancreatitis; CD: Celiac disease; CP: Chronic pancreatitis; HR: Hazard ratio; OR: Odds ratio.

**Table 2 Mechanisms of pancreatic exocrine insufficiency in celiac disease**

|  |  |
| --- | --- |
| **No.** |  |
| 1 | Impaired secretion of cholecystokinin and secretin from the diseased small bowel mucosa |
| 2 | Reduced amino acid uptake in the small bowel, which subsequently leads to reduction in precursors for synthesis of pancreatic enzymes |
| 3 | Morphologic alterations in pancreatic parenchyma secondary to protein malnutrition |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**